Stocks
Citius Oncology, Inc.CTOR
NASDAQHealthcareBiotechnology$0.58
Price as of · delayed, not real-time
A specialty pharmaceutical company focused on developing and commercializing oncology therapies, with its lead product candidate targeting a specific form of non-muscle invasive bladder cancer. The company is in the late-stage clinical development phase and investors track it for its potential to address an unmet medical need in the urologic oncology space.
52W Range: $0.49-$1.93
Congressional Interest in Citius Oncology, Inc. (CTOR)
No congressional trades have been disclosed for Citius Oncology, Inc. (CTOR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CTOR?
No congressional trades found for this stock.